Skip to main content

Table 3 Frequency, bother, and most bothersome atypical antipsychotic AEs reported by patients with schizophrenia

From: Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

 

Schizophrenia, n (%)

(n = 17)

AE Categories

Frequency

Bother

Most Bothersomea

Weight changes

16 (94)

Weight gain and/or increased appetite

16 (94)

12 (71)

7 (41)

 Weight loss and/or decreased appetite

4 (24)

0

0

Low energy

14 (82)

12 (71)

6 (35)

EPS

13 (77)

10 (59)

2 (12)

Somnolence/sedation

12 (71)

 Need to sleep/excessive sleep/excessive sleepiness

11 (65)

6 (35)

1 (6)

 ”Zombie-like”/”out of it”

4 (24)

2 (12)

1 (6)

Anxiety b

11 (65)

8 (47)

6 (35)

Mental anxiety

7 (41)

6 (35)

6 (35)

 Physical anxiety

4 (24)

4 (24)

2 (12)

 Social anxiety

1 (6)

0

1 (6)

Cognitive issues

10 (59)

6 (35)

3 (18)

Sexual function

10 (59)

 Increased sexual desire/activities

2 (12)

1 (6)

1 (6)

 Reduced sexual desire or performance

8 (47)

4 (24)

2 (12)

Increased schizophrenia positive symptoms

8 (47)

7 (41)

4 (24)

Anticholinergic-related dryness

7 (41)

 Dry eyes

1 (6)

0

0

 Dry mouth

6 (35)

5 (29)

3 (18)

 Dry skin

0

0

0

Visual problems

7 (41)

4 (24)

2 (12)

Insomnia

6 (35)

5 (29)

2 (12)

Restlessness/akathisia

6 (35)

3 (18)

3 (18)

Disequilibrium

5 (29)

3 (18)

1 (6)

Cardiovascular

5 (29)

 Hypertension

4 (24)

1 (6)

1 (6)

 Hypotension

1 (6)

1 (6)

1 (6)

QT prolongation/skipped heartbeat

0

0

0

Depressive symptoms

4 (24)

2 (12)

2 (12)

Pain

4 (24)

2 (12)

1 (6)

Bowel/digestive system changes

4 (24)

 Constipation

2 (12)

0

0

 Diarrhea

2 (12)

1 (6)

1 (6)

 Nausea/vomiting

1 (6)

1 (6)

0

Abnormal blood/laboratory test levels

4 (24)

 Anemia

1 (6)

1 (6)

1 (6)

 Hyperglycemia

1 (6)

1 (6)

0

 Hyperlipidemia

2 (12)

1 (6)

1 (6)

Irritability

3 (18)

2 (12)

1 (6)

Anger/aggression

2 (12)

2 (12)

1 (6)

Hypomania

2 (12)

2 (12)

0

Hormonal

2 (12)

1 (6)

1 (6)

Otherc

2 (12)

1 (6)

0

Major medical (diabetes)

2 (12)

1 (6)

1 (6)

Major medical (seizures)

1 (6)

1 (6)

0

Flat/restricted affect

1 (6)

0

0

Social withdrawal

1 (6)

0

0

Major medical (hypothyroidism)

0

0

0

  1. Abbreviations: EPS extrapyramidal symptoms, QT the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle
  2. a The top 5 AEs most frequently reported as most bothersome are highlighted in bold
  3. b Anxiety is reported as the sum of the participants who endorsed any of the anxiety subcodes and also accounts for participants who reported “anxiety” without noting a subcode
  4. c The category of “other” was created to represent select symptoms reported by 2 or fewer participants that were also not reported as most bothersome, most clinically important, or an AE of specific interest